How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,525 results for

Alpha Adrenergic Antagonist

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Letter: Alpha-adrenoceptor-blocking drugs in asthma. (Full text)

Letter: Alpha-adrenoceptor-blocking drugs in asthma. 4154123 1975 01 28 2018 11 13 0007-1447 4 5941 1974 Nov 16 British medical journal Br Med J Letter: Alpha-adrenoceptor-blocking drugs in asthma. 409 Palmer K N KN Gaddie J J Skinner C C eng Clinical Trial Controlled Clinical Trial Journal Article England Br Med J 0372673 0007-1447 0 Adrenergic beta-Antagonists 0 Receptors, Adrenergic QF8SVZ843E Albuterol AIM IM Adrenergic beta-Antagonists therapeutic use Albuterol therapeutic use Asthma drug (...) therapy Drug Synergism Humans Receptors, Adrenergic 1974 11 16 1974 11 16 0 1 1974 11 16 0 0 ppublish 4154123 PMC1612497 Br J Dis Chest. 1972 Apr;66(2):141-6 4402506 Lancet. 1972 Sep 23;2(7778):657 4116809

1974 British medical journal PubMed abstract

102. Effect of alpha-blocking drugs in asthma. (Full text)

Effect of alpha-blocking drugs in asthma. 4150269 1974 05 17 2018 11 13 0007-1447 1 5905 1974 Mar 09 British medical journal Br Med J Effect of alpha-blocking drugs in asthma. 457 Assem E S ES Paterson S S eng Journal Article England Br Med J 0372673 0007-1447 0 Adrenergic beta-Antagonists 0 Receptors, Adrenergic EC 4.6.1.1 Adenylyl Cyclases AIM IM Adenylyl Cyclases metabolism Adrenergic beta-Antagonists therapeutic use Asthma drug therapy Humans Leukocytes drug effects Male Receptors (...) , Adrenergic 1974 3 9 1974 3 9 0 1 1974 3 9 0 0 ppublish 4150269 PMC1633208 Br Med J. 1970 May 30;2(5708):504-7 4193661 Int Arch Allergy Appl Immunol. 1971;40(4-5):576-89 4102844 Clin Allergy. 1973 Jun;3(2):161-75 4131251

1974 British medical journal PubMed abstract

103. Letter: Alpha-adrenoceptor-blocking drugs in asthma. (Full text)

Letter: Alpha-adrenoceptor-blocking drugs in asthma. 234771 1975 06 09 2014 11 20 0007-1447 1 5954 1975 Feb 15 British medical journal Br Med J Letter: Alpha-adrenoceptor-blocking drugs in asthma. 394-5 Airaksinen M M MM Arnala I I Nousiainen T T Kokkola K K eng Journal Article England Br Med J 0372673 0007-1447 0 Adrenergic alpha-Antagonists 0 Adrenergic beta-Agonists AIM IM Adrenergic alpha-Antagonists pharmacology therapeutic use Adrenergic beta-Agonists pharmacology Animals Asthma drug

1975 British medical journal PubMed abstract

104. Antagonism by (+)-amphetamine of the inhibition of [3H]-noradrenaline overflow obtained by alpha-adrenoceptor agonists or bretylium in the perfused cat spleen [proceedings] (Full text)

C eng Journal Article England Br J Pharmacol 7502536 0007-1188 0 Adrenergic alpha-Agonists 0 Bretylium Compounds TZ47U051FI Dextroamphetamine X4W3ENH1CV Norepinephrine IM Adrenergic alpha-Agonists antagonists & inhibitors Animals Bretylium Compounds antagonists & inhibitors Cats Dextroamphetamine pharmacology In Vitro Techniques Norepinephrine metabolism Spleen drug effects metabolism 1979 7 1 1979 7 1 0 1 1979 7 1 0 0 ppublish 43177 PMC2043685 Rev Physiol Biochem Pharmacol. 1977;77:1-124 14389 (...) Antagonism by (+)-amphetamine of the inhibition of [3H]-noradrenaline overflow obtained by alpha-adrenoceptor agonists or bretylium in the perfused cat spleen [proceedings] 43177 1980 04 25 2018 11 13 0007-1188 66 3 1979 Jul British journal of pharmacology Br. J. Pharmacol. Antagonism by (+)-amphetamine of the inhibition of [3H]-noradrenaline overflow obtained by alpha-adrenoceptor agonists or bretylium in the perfused cat spleen [proceedings]. 460P-461P Dubocovich M L ML Langer S Z SZ Moret C

1979 British journal of pharmacology PubMed abstract

105. Letter: Alpha-receptor-blocking drugs in bronchial asthma. (Abstract)

Letter: Alpha-receptor-blocking drugs in bronchial asthma. 46503 1975 05 09 2015 06 16 0140-6736 1 7902 1975 Feb 08 Lancet (London, England) Lancet Letter: Alpha-receptor-blocking drugs in bronchial asthma. 348-9 Patel K R KR Kerr J W JW eng Clinical Trial Journal Article Randomized Controlled Trial England Lancet 2985213R 0140-6736 0 Adrenergic alpha-Antagonists 0 Adrenergic beta-Agonists 0 Drug Combinations L628TT009W Isoproterenol PW8QYA7KI0 Moxisylyte QF8SVZ843E Albuterol Z468598HBV (...) Phentolamine AIM IM Adrenergic alpha-Antagonists administration & dosage therapeutic use Adrenergic beta-Agonists administration & dosage therapeutic use Airway Obstruction drug therapy Airway Resistance drug effects Albuterol therapeutic use Asthma drug therapy Drug Combinations Humans Isoproterenol therapeutic use Moxisylyte therapeutic use Phentolamine therapeutic use Respiratory Therapy 1975 2 8 1975 2 8 0 1 1975 2 8 0 0 ppublish 46503 S0140-6736(75)91271-4

1975 Lancet (London, England)

106. Muscarinic receptor antagonist and an alpha-adrenergic agonist are required in combination to provide stable mydriasis following intravitreal injection in mice (Full text)

Muscarinic receptor antagonist and an alpha-adrenergic agonist are required in combination to provide stable mydriasis following intravitreal injection in mice Tropicamide (muscarinic receptor antagonist) and phenylephrine (α-adrenergic receptor agonist) are commonly used to dilate the pupils by topical application. These two eye drops are often used, singly or in combination, to dilate the pupil and perform acute light-evoked physiological experiments (electroretinography, for example), before (...) full and stable pupillary dilation following intravitreal injections. Re-instillation of topical mydriatics after intravitreal injections was required for maximal pupillary dilation. A combination of a muscarinic receptor antagonist and an alpha-adrenergic agonist is required for stable mydriasis following intravitreal injection.

2010 Biology and medicine (Aligarh) PubMed abstract

107. The alpha(2) adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates. (Abstract)

The alpha(2) adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates. Reduction in the antiparkinsonian benefit of levodopa is a major complication of long-term levodopa treatment in advanced Parkinson's disease (PD). Such loss of benefit arises because of reduced duration of action and appearance of disabling dyskinesia. We assess the potential of the α(2) adrenergic antagonist fipamezole to reduce motor complications in parkinsonian macaques. MPTP (...) to that provided by the higher dose levodopa alone. However, with the combination, antiparkinsonian benefit was of much better quality. The proportion of on time without disabling dyskinesia (79%) was significantly greater than that with high dose levodopa alone (45%). Increased duration and quality of levodopa action may represent therapeutically valuable actions of α(2) adrenergic antagonists.

2010 Movement Disorders

108. Blockade of intra-articular adrenergic receptors increases analgesic demands for pain relief after knee surgery. (Abstract)

examined the expression of opioid peptides and adrenergic receptors in cells infiltrating inflamed synovial tissue and we hypothesized that intra-articular (i.a.) administration of the adrenergic receptor antagonist labetalol will increase postoperative analgesic consumption and/or pain intensity in these patients. In a double-blind, randomized manner, 75 patients undergoing therapeutic knee arthroscopy received i.a. placebo (20 ml saline) or labetalol (2.5 or 5 mg in 20 ml saline) at the end (...) of surgery. Postoperative pain intensity was assessed by visual analog and verbal rating scales at rest and on exertion, and by the consumption of morphine via patient-controlled analgesia. Synovial biopsies were taken during the operation for double-immunofluorescence confocal microscopy studies. Alpha(1)- and beta(2)-adrenergic receptors were co-expressed in opioid peptide-containing cells. No significant difference was seen in pain scores, but patients receiving 2.5 mg labetalol requested

2011 Rheumatology international Controlled trial quality: uncertain

109. DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury

Severe TBI TBI Catecholamines Heart rate variability Adrenergic alpha-Agonists Adrenergic beta-Antagonists Cognitive Impairment Additional relevant MeSH terms: Layout table for MeSH terms Wounds and Injuries Brain Injuries Brain Injuries, Traumatic Hyperkinesis Craniocerebral Trauma Trauma, Nervous System Brain Diseases Central Nervous System Diseases Nervous System Diseases Dyskinesias Neurologic Manifestations Signs and Symptoms Propranolol Clonidine Adrenergic Agents Adrenergic beta-Antagonists (...) Adrenergic Antagonists Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Vasodilator Agents Analgesics Sensory System Agents Peripheral Nervous System Agents Sympatholytics Autonomic Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists

2011 Clinical Trials

110. Effects of Adrenergic Drugs on the Fluid Balance During Surgery

System Diseases Pharmaceutical Solutions Phenylephrine Oxymetazoline Adrenergic Agents Esmolol Adrenergic Agonists Cardiotonic Agents Mydriatics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Sympathomimetics Vasoconstrictor Agents Nasal Decongestants Respiratory System Agents Adrenergic alpha-1 Receptor Agonists Adrenergic alpha-Agonists Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Protective Agents Adrenergic beta-1 Receptor Antagonists (...) infusion 0.01 µg/kg/min of the alpha-1-adrenergic receptor agonist phenylephrine Other Name: Drug by Hefeng Pharmaceutical Co, Shanghai, China. Placebo Comparator: Lactated Ringer´s solution 10 ml/h lactated Ringer's solution without active drug was infused intravenously over 3 hours. Drug: Lactated Ringer´s solution Intravenous Infusion of 10 ml/h lactated Ringer's solution that contained no drug Outcome Measures Go to Primary Outcome Measures : Urinary excretion [ Time Frame: 3 hours ] Urine

2011 Clinical Trials

111. Meta-analysis of the efficacy and safety of alpha2-adrenergic agonists, beta-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs. (Full text)

Meta-analysis of the efficacy and safety of alpha2-adrenergic agonists, beta-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs. To perform a meta-analysis to estimate the intraocular pressure (IOP)-lowering efficacy and safety of alpha(2)-adrenergic agonists (AAs), beta-adrenergic antagonists (BBs), and topical carbonic anhydrase inhibitors (TCAIs) when used in combination with a prostaglandin analog (PGA).MEDLINE, Embase, and the Cochrane Controlled

2010 Archives of ophthalmology PubMed abstract

112. Doxazosin an a1 Antagonist for Alcohol Dependence

Alcohol craving Additional relevant MeSH terms: Layout table for MeSH terms Alcoholism Alcohol-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Ethanol Doxazosin Anti-Infective Agents, Local Anti-Infective Agents Central Nervous System Depressants Physiological Effects of Drugs Antihypertensive Agents Adrenergic alpha-1 Receptor Antagonists Adrenergic alpha-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms (...) that the noradrenergic (NE) system is involved in the neurobiology of AD, thus representing an interesting new pharmacotherapy target and the theoretical rationale for this proposal. Consistent with the concept that the NE system may represent a new pharmacological target for AD, recent studies have shown that the prototype alpha-1 NE receptor antagonist prazosin reduces alcohol drinking in different animal models. Furthermore, clinical evidence has also confirmed that prazosin appears to be efficacious in reducing

2011 Clinical Trials

113. Canadian guidelines on opioid use disorder among older adults

for opioid withdrawal management? RECOMMENDATION #13: Opioid withdrawal management should only be offered in the context of connection to long-term addiction treatment. [GRADE Quality: Moderate; Strength: Strong] RECOMMENDATION #14: Induction onto an opioid agonist is recommended over a non- opioid treatment withdrawal management in older adults with an OUD. If a trial of tapering is attempted, there should be the option to initiate longer-term opioid agonist therapy or opioid antagonist therapy. [GRADE (...) by the consequences of their drug use (Bachi et al ., 2017) . T he term “opioid” refers to any substance that binds to an opioid receptor . Endogenous opioid peptides (e .g ., endorphins), natural or synthetic exogenous opioid receptor agonists (e .g ., morphine), and opioid receptor antagonists (e .g ., naloxone) are all, by definition, opioids (Inturrisi et al ., 2018) . For the purpose of this guideline, however, the term opioid will be restricted to the description of natural or synthetic exogenous full

2019 CPG Infobase

116. An Observational Study of Dutasteride and Alpha-blocker Combination Therapy in Men With Symptomatic Benign Prostatic Hyperplasia and PSA Level Over 4 ng/mL

Adrenergic alpha-Antagonists 5-alpha Reductase Inhibitors Steroid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents (...) An Observational Study of Dutasteride and Alpha-blocker Combination Therapy in Men With Symptomatic Benign Prostatic Hyperplasia and PSA Level Over 4 ng/mL An Observational Study of Dutasteride and Alpha-blocker Combination Therapy in Men With Symptomatic Benign Prostatic Hyperplasia and PSA Level Over 4 ng/mL - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record

2011 Clinical Trials

117. Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH)

relevant MeSH terms: Layout table for MeSH terms Hyperplasia Prostatic Hyperplasia Pathologic Processes Prostatic Diseases Genital Diseases, Male Adrenergic alpha-Antagonists 5-alpha Reductase Inhibitors Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Steroid Synthesis Inhibitors Enzyme Inhibitors Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists (...) Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH) Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You

2011 Clinical Trials

119. Management of stable angina

revascularisation Completely revised 5.8.3 Enhanced counterpulsation Completely revised 5.8.4 Other approaches New 6 Stable angina and non-cardiac surgery Completely revised 6.1 Assessment prior to surgery Minor update 6.2 Perioperative revascularisation Minor update 6.3 Drug therapy in patients undergoing non-cardiac surgery Completely revised 6.3.1 Beta blockers Completely revised 6.3.2 Alpha 2 adrenergic receptor agonists Completely revised 6.3.4 Antiplatelet therapy Completely revised 6.3.5 Statins (...) that, following an Independent Review Panel Assessment: ranolazine (Ranexa®) is not recommended for use within NHS Scotland. Indication under review: as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta blockers and/or calcium antagonists). The submitting company did not present a sufficiently robust clinical and economic case to gain acceptance by the Independent Review Panel

2018 SIGN

120. Management of opioid use disorders: a national clinical practice guideline

. The recommendations in this guideline are based on the clin- ical evidence base regarding treatment approaches for opioid use disorder currently available in Canada, including oral opioid agonist treatment and antagonist pharmacotherapies, as well as withdrawal management strategies, residential treatment and psychosocial treatment interventions. The evidence base for pharmacotherapies not yet widely available in Canada, including long-acting and extended-release opioid antagonists, as well as injectable opioid (...) - tages of methadone and buprenorphine–naloxone are summarized in Table 2. Compared with use of a 2 -adrenergic agonists or psychosocial treatment alone, opioid agonist treatment with buprenorphine– naloxone or methadone has proven superior in terms of reten- tion in treatment, sustained abstinence from illicit opioid use, and reduced risk of morbidity and death. 21,25,37–40 Recent meta- analyses have found that buprenorphine–naloxone and metha- done were essentially equally efficacious across

2018 CPG Infobase

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>